PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka America Pharmaceutical, Inc., (OAPI) and Otsuka Pharmaceutical, Co., Ltd. (Otsuka) announce that the U.S. Food and Drug Administration (FDA) plans to ...
Whether brexpiprazole (Rexulti) is effective as adjunctive treatment for post-traumatic stress disorder (PTSD) will be debated at an FDA advisory committee meeting on Friday. The atypical ...
FDA's outside experts weren't sold on the trial data for brexpiprazole (Rexulti) as an adjunctive treatment for post-traumatic stress disorder (PTSD), sinking its prospects for approval in this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results